
Lifecore Biomedical, Inc.: stock overview
Price
$6.39
November 20, 2026Market cap $239M
What Ploutos Investor adds for Lifecore Biomedical
Part of Ploutos Investor, €9.99 a month
- The full history: 16 fiscal years, from FY2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
- The latest annual figures the company filed are for 2025, more than a year ago. Newer ones may be late.
In short
Lifecore Biomedical had revenue of $129M in the fiscal year to May 25, 2025 and a net loss of $39M. Revenue fell by 4.2% a year on average over the last 5 years. It pays no dividend.
From its SEC filings (latest fiscal year to May 25, 2025) and the price of November 20, 2026.
Its SEC filings- Market cap
- $239M
- 37.41M shares
- P/E
- –
- Revenue, fiscal year
- $129M
- -4.2% a year over 5 years
- Net margin
- -30.0%
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
+11.7% a year over 2 years
Fiscal years in figures
LFCR's revenue, profit, cash flow and dividend with each year-end price, from FY2010 to FY2022, 13 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $241M
- $239M
- Enterprise value
- –
- P/E
- –
- EV / EBIT
- –
- EV / Revenue
- –
- P/B
- –
- FCF yield
- –
- Earnings yield 3-year median: -18.9%
- –
Profitability
- Gross margin
- 31.3%
- Operating margin
- -13.4%
- Net margin 3-year median: -30.0%
- -30.0%
- ROIC
- -10.1%
- ROIC, 5-year average
- -8.9%
- ROE
- –
Growth
- Revenue, yearly change
- +0.5%
- EPS, yearly change
- -484.8%
- FCF, yearly change
- –
- Revenue, average a year
- -4.2%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $23M
- Total debt
- –
- Net cash
- –
- Net debt / EBITDA
- –
- Interest cover
- -0.8x
- Current ratio
- 3.84
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +21.1%
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- LIFECORE BIOMEDICAL, INC. \DE\
- CIK
- 1005286
- Exchange
- NASDAQ
- Industry (SIC)
- 2834 · Pharmaceutical Preparations
- Fiscal year ends
- May 25
- Latest annual report
- May 25, 2025
- Reporting currency
- USD
- Shares
- 37.41M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with LFCR
- JNJJohnson & Johnson+0,00%Compare with LFCR
- ABBVAbbVie+0,00%Compare with LFCR
- UNHUnitedHealth+0,00%Compare with LFCR
- MRKMerck & Company+0,00%Compare with LFCR
- AMGNAmgen+0,00%Compare with LFCR
- TMOThermo Fisher Scientific+0,00%Compare with LFCR
- ABTAbbott Laboratories+0,00%Compare with LFCR
The full analysis
What do Lifecore Biomedical's filings show?
These are Lifecore Biomedical's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is LFCR's market cap?
Lifecore Biomedical, Inc.'s market cap is $239M, at a price of $6.39 on November 20, 2026 and 37.41M shares.
How much revenue does LFCR have?
Lifecore Biomedical had revenue of $129M in the fiscal year to May 25, 2025. Over the last 5 years it changed by -4.2% a year on average.
Does LFCR pay a dividend?
No. Lifecore Biomedical paid no regular dividend over the last 12 months.
Where do the figures come from?
From Lifecore Biomedical, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.